Ellsworth Advisors’s Sanofi SNY Stock Holding History

Ellsworth Advisors’s Portfolio SNY Stock Details SNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-17,694	Closed	-$880K	–	200
2023 Q4	$880K	Buy	17,694 +1,871	+12%	+$91.5K	0.28%	82
2023 Q3	$828K	Buy	15,823 +4,650	+42%	+$248K	0.29%	74
2023 Q2	$602K	Buy	11,173 +405	+4%	+$21.8K	0.21%	86
2023 Q1	$586K	Buy	10,768 +1,806	+20%	+$87.8K	0.21%	77
2022 Q4	$441K	Buy	+8,962	New	+$393K	0.17%	99

Other funds holding SNY

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Ellsworth Advisors's SNY Position: Q1 2024 in Review

Ellsworth Advisors sold out of Sanofi (SNY) in Q1 2024, closing a stake of 17,694 shares — an estimated $880K sold.

Ellsworth Advisors first reported a position in SNY in Q4 2022 and held it in 5 quarters. The position peaked at $880K in Q4 2023. 713 funds tracked by Wall St. Rank hold SNY as of Q1 2024.

Ellsworth Advisors reported no remaining Sanofi position as of Q1 2024 after selling out during the quarter.
Ellsworth Advisors sold 17,694 Sanofi shares in Q1 2024, an estimated $880K.
Ellsworth Advisors first reported a position in Sanofi in Q4 2022 and held it in 5 quarters.
Ellsworth Advisors's Sanofi position peaked at $880K in Q4 2023.
713 funds tracked by Wall St. Rank held Sanofi as of Q1 2024.

Based on Ellsworth Advisors's 13F filing for Q1 2024, filed 15 Apr 2024.